GLP-1 receptor agonists may be considered when additional treatment goals include weight reduction, improved glycemic control, chronic kidney disease risk reduction, or lowering atherosclerotic cardiovascular risk, particularly in patients with obesity or established Atherosclerotic Cardiovascular Disease (ASCVD) [7, 16, 47]
A well-planned clinical approach helps reduce the chance of nausea or blood sugar fluctuations
As a result, the atria dont contract or pump blood into the ventricles as they should, leading to irregular ventricular contractions and a fast, irregular heartbeat (4, 24)
reduction in adipose mass therefore diminishes this inflammatory source
Glutathione levels begin to decline naturally in the body after the age of 40
What are the licensed alternatives to retatrutide and tesamorelin for weight management in the UK